Cargando…
Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153540/ https://www.ncbi.nlm.nih.gov/pubmed/36519322 http://dx.doi.org/10.3324/haematol.2022.281402 |
| _version_ | 1785035949355302912 |
|---|---|
| author | Bye, Alexander P. Kriek, Neline Sage, Tanya Rawlings, Suzannah J. Prodger, Catherine Kesavan, Murali Lees, Charlotte Booth, Stephen Cowen, Louise G Shefferd, Kirsty Desborough, Michael J. Gibbins, Jonathan M. Eyre, Toby A. |
| author_facet | Bye, Alexander P. Kriek, Neline Sage, Tanya Rawlings, Suzannah J. Prodger, Catherine Kesavan, Murali Lees, Charlotte Booth, Stephen Cowen, Louise G Shefferd, Kirsty Desborough, Michael J. Gibbins, Jonathan M. Eyre, Toby A. |
| author_sort | Bye, Alexander P. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10153540 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101535402023-05-03 Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib Bye, Alexander P. Kriek, Neline Sage, Tanya Rawlings, Suzannah J. Prodger, Catherine Kesavan, Murali Lees, Charlotte Booth, Stephen Cowen, Louise G Shefferd, Kirsty Desborough, Michael J. Gibbins, Jonathan M. Eyre, Toby A. Haematologica Letter to the Editor Fondazione Ferrata Storti 2022-12-15 /pmc/articles/PMC10153540/ /pubmed/36519322 http://dx.doi.org/10.3324/haematol.2022.281402 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letter to the Editor Bye, Alexander P. Kriek, Neline Sage, Tanya Rawlings, Suzannah J. Prodger, Catherine Kesavan, Murali Lees, Charlotte Booth, Stephen Cowen, Louise G Shefferd, Kirsty Desborough, Michael J. Gibbins, Jonathan M. Eyre, Toby A. Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib |
| title | Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib |
| title_full | Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib |
| title_fullStr | Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib |
| title_full_unstemmed | Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib |
| title_short | Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib |
| title_sort | pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153540/ https://www.ncbi.nlm.nih.gov/pubmed/36519322 http://dx.doi.org/10.3324/haematol.2022.281402 |
| work_keys_str_mv | AT byealexanderp pirtobrutinibresultsinreversibleplateletdysfunctioncomparedtoibrutinibandacalabrutinib AT kriekneline pirtobrutinibresultsinreversibleplateletdysfunctioncomparedtoibrutinibandacalabrutinib AT sagetanya pirtobrutinibresultsinreversibleplateletdysfunctioncomparedtoibrutinibandacalabrutinib AT rawlingssuzannahj pirtobrutinibresultsinreversibleplateletdysfunctioncomparedtoibrutinibandacalabrutinib AT prodgercatherine pirtobrutinibresultsinreversibleplateletdysfunctioncomparedtoibrutinibandacalabrutinib AT kesavanmurali pirtobrutinibresultsinreversibleplateletdysfunctioncomparedtoibrutinibandacalabrutinib AT leescharlotte pirtobrutinibresultsinreversibleplateletdysfunctioncomparedtoibrutinibandacalabrutinib AT boothstephen pirtobrutinibresultsinreversibleplateletdysfunctioncomparedtoibrutinibandacalabrutinib AT cowenlouiseg pirtobrutinibresultsinreversibleplateletdysfunctioncomparedtoibrutinibandacalabrutinib AT shefferdkirsty pirtobrutinibresultsinreversibleplateletdysfunctioncomparedtoibrutinibandacalabrutinib AT desboroughmichaelj pirtobrutinibresultsinreversibleplateletdysfunctioncomparedtoibrutinibandacalabrutinib AT gibbinsjonathanm pirtobrutinibresultsinreversibleplateletdysfunctioncomparedtoibrutinibandacalabrutinib AT eyretobya pirtobrutinibresultsinreversibleplateletdysfunctioncomparedtoibrutinibandacalabrutinib |